CY1110185T1 - Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19 - Google Patents

Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19

Info

Publication number
CY1110185T1
CY1110185T1 CY20101100651T CY101100651T CY1110185T1 CY 1110185 T1 CY1110185 T1 CY 1110185T1 CY 20101100651 T CY20101100651 T CY 20101100651T CY 101100651 T CY101100651 T CY 101100651T CY 1110185 T1 CY1110185 T1 CY 1110185T1
Authority
CY
Cyprus
Prior art keywords
protein
modified
cabin
parvovirus
capsid protein
Prior art date
Application number
CY20101100651T
Other languages
English (en)
Inventor
Susanne Modrow
Torsten Lowin
Markus Möbs
Michael Bröker
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of CY1110185T1 publication Critical patent/CY1110185T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14211—Erythrovirus, e.g. B19 virus
    • C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Η εφεύρεση αφορά τροποποιημένη πρωτεΐνη VP1-καψιδίου του παρβοϊού Β19 που έχει μειωμένη δραστικότητα ενζύμου που ομοιάζει με φωσφολιπάση Α2 εν συγκρίσει προς την πρωτεΐνη VP1-καψιδίου του παρβοϊού Β19 άγριου τύπου που έχει την αλληλουχία αμινοξέος της SeqID 1.
CY20101100651T 2004-09-24 2010-07-13 Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19 CY1110185T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04450180 2004-09-24
EP05799042A EP1791858B1 (en) 2004-09-24 2005-09-23 Modified vp1-capsid protein of parvovirus b19

Publications (1)

Publication Number Publication Date
CY1110185T1 true CY1110185T1 (el) 2015-01-14

Family

ID=35809798

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100651T CY1110185T1 (el) 2004-09-24 2010-07-13 Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19

Country Status (9)

Country Link
US (2) US9573979B2 (el)
EP (2) EP1791858B1 (el)
AT (1) ATE465173T1 (el)
CY (1) CY1110185T1 (el)
DE (1) DE602005020815D1 (el)
ES (2) ES2556710T3 (el)
PL (1) PL1791858T3 (el)
PT (1) PT1791858E (el)
WO (1) WO2006032697A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
EP2446898A1 (en) * 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
WO2012055814A1 (en) 2010-10-25 2012-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
EP4206216A1 (en) 2016-05-13 2023-07-05 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
PE20201264A1 (es) 2017-09-20 2020-11-19 4D Molecular Therapeutics Inc Variantes de capsides de virus adenoasociados y metodos de uso de estas
DK3717636T3 (da) 2017-11-27 2023-05-30 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
JP2022520875A (ja) 2019-02-25 2022-04-01 ノバルティス アーゲー Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
EP3931334A1 (en) 2019-02-25 2022-01-05 Novartis AG Compositions and methods to treat bietti crystalline dystrophy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
EP0983289A4 (en) 1997-05-19 2001-04-25 Merck & Co Inc OLIGONUCLEOTIDE ADJUVANT
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
SE520177C2 (sv) * 1998-11-24 2003-06-03 Kristina Broliden Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1275658B1 (en) * 2001-07-10 2006-11-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis

Also Published As

Publication number Publication date
ATE465173T1 (de) 2010-05-15
PL1791858T3 (pl) 2010-09-30
WO2006032697A3 (en) 2006-05-18
EP2149583A1 (en) 2010-02-03
US9573979B2 (en) 2017-02-21
EP1791858A2 (en) 2007-06-06
WO2006032697A2 (en) 2006-03-30
PT1791858E (pt) 2010-07-26
ES2344739T3 (es) 2010-09-06
ES2556710T3 (es) 2016-01-19
DE602005020815D1 (de) 2010-06-02
EP1791858B1 (en) 2010-04-21
EP2149583B1 (en) 2015-10-28
US20070286870A1 (en) 2007-12-13
US20170260239A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
CY1110185T1 (el) Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
NO20063624L (no) FC region varianter
EA201000040A1 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
DE60235761D1 (de) Isoform des vegfs
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
ATE391781T1 (de) Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
DE60332320D1 (de) Neues screening-verfahren
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
DE602007004110D1 (de) Hausstaubmilbenallergen
DE602006014530D1 (de) Pharmazeutisch aktive diazepane
ATE493432T1 (de) Gewinnung von hitzeschockproteinen
WO2006096690A3 (en) Compositions and methods for inhibiting g protein signaling
EP1801232A4 (en) METHOD FOR SORTING TRANSMEMBRANE ENZYME INHIBITOR SUBSTANCE
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
ATE421698T1 (de) Intrinsic-faktor vom schwein
DK1602721T3 (da) Phospholipase A SB 2 /SB stammende fra Koji-skimmelsvamp
ATE511644T1 (de) Neues screening-verfahren
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung